DAWN

7.93

1.73% -0.14

After Hours: 7.71 -0.22 -2.77%

Day One Biopharmaceuticals Inc (DAWN)

Overview News Price History Option Chain Financials Discussions Forecast

Day One Biopharmaceuticals Inc stock is traded at $7.93, with a volume of 1.27M. It is down -1.73% in the last 24 hours and down -12.47% over the past month.

Previous Close:

$8.07

Open:

$7.78

24h Volume:

1.27M

Relative Volume:

1.18

Market Cap:

$830.09M

Revenue:

Net Income/Loss:

$-167.48M

P/E Ratio:

-4.0667

EPS:

-1.95

Net Cash Flow:

$-197.47M

1W Performance:

-4.57%

1M Performance:

-12.47%

6M Performance:

-43.07%

1Y Performance:

-52.00%

1-Day Range:

$7.54

$7.96

1-Week Range:

$7.54

$8.39

52-Week Range:

$7.54

$18.07

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Name

Day One Biopharmaceuticals Inc

Sector

Healthcare (1164)

Industry

Biotechnology (681)

Phone

650 484-0899

Address

2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

DAWN's Discussions on Twitter

Compare DAWN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DAWN Day One Biopharmaceuticals Inc	7.93	830.09M	0	-167.48M	-197.47M	-1.95
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-24	Reiterated	Needham	Buy
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy
Apr-24-24	Reiterated	Needham	Buy
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform
Feb-08-23	Initiated	CapitalOne	Overweight
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Dec-05-22	Initiated	Goldman	Buy
Dec-01-22	Initiated	BofA Securities	Buy

View All

Day One Biopharmaceuticals Inc Stock (DAWN) Latest News

Mar 29, 2025

Swiss National Bank Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World

Mar 29, 2025

Mar 25, 2025

Charles Schwab Investment Management Inc. Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World

Mar 25, 2025

Mar 20, 2025

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Position Boosted by Bank of New York Mellon Corp - Defense World

Mar 20, 2025

Mar 12, 2025

Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential - TipRanks

Mar 12, 2025

Mar 09, 2025

(DAWN) Proactive Strategies - Stock Traders Daily

Mar 09, 2025

Mar 08, 2025

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Mar 08, 2025

Mar 07, 2025

Rhumbline Advisers Has $957,000 Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World

Mar 07, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 5.5% on Analyst Downgrade - Defense World

Mar 07, 2025

JPMorgan Chase & Co. Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $34.00 - Defense World

Mar 07, 2025

Mar 05, 2025

Needham & Company LLC Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat

Mar 01, 2025

What is Wedbush’s Forecast for DAWN Q1 Earnings? - Defense World

Mar 01, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Quarterly Earnings Results, Misses Estimates By $0.34 EPS - MarketBeat

Mar 01, 2025

Feb 28, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Misses Expectations By $0.34 EPS - MarketBeat

Feb 28, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low After Earnings Miss - MarketBeat

Feb 28, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $36.00 Price Target at HC Wainwright - MarketBeat

Feb 28, 2025